It was certainly unexpected by many that transcatheter aortic valve implantation became so widely used 2-3 years after CE mark approval.Two main reasons justified this massive interest and widespread adoption:
1. A genuine need to treat a large number of patients, with degenerative aortic stenosis in their advanced age, who had multiple comorbidities and high mortality with conventional aortic valve replacement.
2. The development of a spirit of cooperation among all the physicians involved, motivated by the general acceptance that this practice involved the combination of surgical and interventional skills and expert interpretation of multimodality imaging.
The anatomical complexity of the mitral valve and variety of pathological processes, a clinical challenge also for experienced surgeons with direct access and repair, deterred for years any attempt to percutaneous correction. Mitral regurgitation can be caused by annular dilatation and leaflet tenting for functional regurgitation secondary to left ventricular dilatation, including post-ischaemic failure, or can be secondary to leaflet and cordal mixomatous degeneration or, more rarely, post-rheumatic inflammatory changes. Comparison of the results of the TMVR with the outcome predicted by longitudinal studies of the natural history of medically treated mitral regurgitation. Correlation between completeness of the correction of MR and improvement of symptons and MACE free survival.
12 countries were involved in the pilot phase of the TCVT Registry (2010-2013): Belgium, Czech Republic, Denmark, France, Germany, Israel, Italy, Poland, Spain, Switzerland, UK and Sweden. In December 2012 EuroIntervention published: in-hospital results on 4,571 patients for the TCVT Registry. The one month follow-up were presented at the ESC Congress in Munich.
After the pilot, the TCVT Registry moved into its long-term phase, in which the 56 ESC member countries were invited to take part.
The Executive Committee of the registry is chaired by Martine Gilard
Martine Gilard (Chairperson)Carlo Di Mario (Past Chairperson)Bernard Prendergast (Aortic)Neil Moat (Aortic)Bernard Iung (Aortic)Stephan Windecker (Aortic)Patrizio Lancellotti (Aortic/Mitral)Francesco Maisano (Mitral)Susanna Price (Mitral)Robert Ferrari (Oversight Committee)Aldo Maggioni, EORP Scientific Coordinator, ex-officio (non-voting)
The Steering Committee is composed of one National Coordinator per participating country. The National Cardiac Societies are responsible for the selection of the national coordinators and participating centres.
Johan Bosmans, BEMarc Claeys, BEPeter Wenaweser, CHGeorgios M. Georgiou, CYPetr Kala, CZMikko Savontaus, FIHerve Le Breton, FRPeter Ludman, GBKonstantinos Toutouzas, GRBela Merkely, HUAmit Segev, ILSergio Berti, ITGian Paolo Ussia, ITSigitas Cesna, LTGiedrius Davidavicius, LTInga Narbute, LVAndrew Cassar, MTMarian Zembala, PLRui Campante Teles, PTMilan Nedeljkovic, RSSimon Matskeplishvili, RUMatjaz Bunc, SIViliam Fridrich, SK
Carlo Di Mario (Chairman)Neil Moat (Aortic)Pepe Zamorano (Aortic)Gerhard Schuler (Aortic)Bernard Iung (Aortic)Olaf Franzen (Mitral)Ottavio Alfieri (Mitral)Susanna Price (Mitral)Luigi Tavazzi (Oversight Committee)Aldo Maggioni (EORP)
Belgium: Erwin Schroeder (Aortic) / Marc Claeys (Mitral)Czech Republic: Petr KalaFrance: Helene EltchaninoffGermany: Georg Nickenig (Mitral)Israel: Haim DanenbergItaly: Francesco Romeo (Aortic) / Gian Paolo Ussia (Mitral)Poland: Marian ZembalaSpain: Javier GoicoleaSwitzerland: Peter Wenaweser (Aortic) / Roberto Corti (Mitral)United Kingdom: Bernard Prendergast
If you wish to know more about this survey please contact EORP or click how to join us.
Thanks to Edwards Lifesciences LLC, Irvine, CA. for the picture. Edwards SAPIEN and SAPIEN are trademarks of Edwards Lifesciences Corporation.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved